TY - JOUR AU - del Carmen, M. G. AU - Birrer, M. AU - Schorge, J. O. PY - 2012 DA - 2012// TI - Carcinosarcoma of the ovary: a review of the literature JO - Gynecol Oncol VL - 125 UR - https://doi.org/10.1016/j.ygyno.2011.12.418 DO - 10.1016/j.ygyno.2011.12.418 ID - del Carmen2012 ER - TY - JOUR AU - Paulsson, G. AU - Anderson, S. AU - Sorbe, B. PY - 2013 DA - 2013// TI - A population-based series of ovarian carcinosarcomas with long-term follow-up JO - Anticancer Res VL - 33 ID - Paulsson2013 ER - TY - BOOK PY - 2012 DA - 2012// TI - SEER cancer statistics review, 1975–2009 PB - National Cancer Institute CY - Bethesda ID - ref3 ER - TY - JOUR AU - Kyoung-Chul, C. AU - Jae-Joon, K. AU - Dae-Yeon, K. AU - Jong-Hyeok, K. AU - Yong-Man, K. AU - Joo-Hyun, N. PY - 2011 DA - 2011// TI - Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience JO - Gynecol Ostet Invest VL - 72 UR - https://doi.org/10.1159/000323775 DO - 10.1159/000323775 ID - Kyoung-Chul2011 ER - TY - JOUR PY - 2014 DA - 2014// TI - FIGO staging for carcinoma of the vulva, cervix, and corpus uteri JO - Int J Gynaecol Obstet VL - 125 UR - https://doi.org/10.1016/j.ijgo.2014.02.003 DO - 10.1016/j.ijgo.2014.02.003 ID - ref5 ER - TY - JOUR AU - Brown, E. AU - Stewart, M. AU - Rye, T. AU - Al-Nafussi, A. AU - Williams, A. R. AU - Bradburn, M. PY - 2004 DA - 2004// TI - Carcinosarcoma of the ovary: 19 years of prospective data from a single center JO - Cancer VL - 100 UR - https://doi.org/10.1002/cncr.20256 DO - 10.1002/cncr.20256 ID - Brown2004 ER - TY - JOUR AU - D’Angelo, E. AU - Prat, J. PY - 2011 DA - 2011// TI - Pathology of mixed Müllerian tumours JO - Best Pract Res Clin Obstet Gynaecol VL - 25 UR - https://doi.org/10.1016/j.bpobgyn.2011.05.010 DO - 10.1016/j.bpobgyn.2011.05.010 ID - D’Angelo2011 ER - TY - JOUR AU - Rauh-Hain, J. A. AU - Growdon, W. B. AU - Rodriguez, N. PY - 2011 DA - 2011// TI - Carcinosarcoma of the ovary: a case-control study JO - Gynecol Oncol VL - 121 UR - https://doi.org/10.1016/j.ygyno.2011.02.023 DO - 10.1016/j.ygyno.2011.02.023 ID - Rauh-Hain2011 ER - TY - JOUR AU - Dictor, M. PY - 1985 DA - 1985// TI - Malignant mixed mesodermal tumor of the ovary: a report of 22 cases JO - Obstet Gynecol VL - 65 ID - Dictor1985 ER - TY - JOUR AU - Berton-Rigaud, D. AU - Devouassoux-Shisheboran, M. AU - Ledermann, J. A. AU - Leitao, M. M. AU - Powell, M. A. AU - Poveda, A. PY - 2014 DA - 2014// TI - Gynecologic Cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma JO - Int J Gynecol Cancer VL - 24 UR - https://doi.org/10.1097/IGC.0000000000000228 DO - 10.1097/IGC.0000000000000228 ID - Berton-Rigaud2014 ER - TY - JOUR AU - Cicin, I. AU - Saip, P. AU - Eralp, Y. AU - Selam, M. AU - Topuz, S. AU - Ozluk, Y. PY - 2008 DA - 2008// TI - Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum JO - Gynecol Oncol VL - 108 UR - https://doi.org/10.1016/j.ygyno.2007.09.003 DO - 10.1016/j.ygyno.2007.09.003 ID - Cicin2008 ER - TY - JOUR AU - Shylasree, T. S. AU - Bryant, A. AU - Athavale, R. PY - 2013 DA - 2013// TI - Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma JO - Cochrane Database Syst Rev VL - 28 ID - Shylasree2013 ER - TY - JOUR AU - Ardighieri, L. PY - 2016 DA - 2016// TI - Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship JO - Virchows Arch VL - 469 UR - https://doi.org/10.1007/s00428-016-1933-x DO - 10.1007/s00428-016-1933-x ID - Ardighieri2016 ER - TY - JOUR AU - Zhao, S. AU - Bellone, S. AU - Lopez, S. AU - Thakral, D. AU - Schwab, C. AU - English, D. P. PY - 2016 DA - 2016// TI - Mutational landscape of uterine and ovarian carcinosarcoma implicates histone genes in epithelial-mesenchymal transition JO - Proc Natl Acad Sci U S A VL - 113 UR - https://doi.org/10.1073/pnas.1614120113 DO - 10.1073/pnas.1614120113 ID - Zhao2016 ER - TY - JOUR AU - Sharon, E. AU - Streicher, H. AU - Goncalves, P. AU - Chen, H. X. PY - 2014 DA - 2014// TI - Immune checkpoint inhibitors in clinical trials JO - Chin J Cancer VL - 33 UR - https://doi.org/10.5732/cjc.014.10122 DO - 10.5732/cjc.014.10122 ID - Sharon2014 ER - TY - JOUR AU - Webb, J. R. AU - Milne, K. AU - Kroeger, D. R. AU - Nelson, B. H. PY - 2016 DA - 2016// TI - PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer JO - Gynecol Oncol VL - 141 UR - https://doi.org/10.1016/j.ygyno.2016.03.008 DO - 10.1016/j.ygyno.2016.03.008 ID - Webb2016 ER - TY - STD TI - Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J Clin Oncol. 2015;33(suppl 5510):5510. ID - ref17 ER - TY - JOUR AU - Mittica, G. AU - Genta, S. AU - Aglietta, M. AU - Valabrega, G. PY - 2016 DA - 2016// TI - Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer? JO - Int J Mol Sci VL - 17 UR - https://doi.org/10.3390/ijms17071169 DO - 10.3390/ijms17071169 ID - Mittica2016 ER - TY - JOUR AU - Hamanishi, J. AU - Mandai, M. AU - Ikeda, T. AU - Minami, M. AU - Kawaguchi, A. AU - Murayama, T. PY - 2015 DA - 2015// TI - Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.62.3397 DO - 10.1200/JCO.2015.62.3397 ID - Hamanishi2015 ER - TY - STD TI - Disis ML, Patel MR, Pant S, Hamilton EP, Lockhart AC, Kelly K, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical activity. J Clin Oncol. 2016;34(suppl 5533):5533. ID - ref20 ER - TY - JOUR AU - Mole, R. H. PY - 1953 DA - 1953// TI - Whole body irradiation: radiobiology or medicine? JO - Br J Radiol VL - 26 UR - https://doi.org/10.1259/0007-1285-26-305-234 DO - 10.1259/0007-1285-26-305-234 ID - Mole1953 ER - TY - CHAP AU - Drake, C. ED - DeWeese, T. L. ED - Laiho, M. PY - 2011 DA - 2011// TI - Radiation-induced immune modulation BT - Molecular determinants of radiation response PB - Springer CY - New York UR - https://doi.org/10.1007/978-1-4419-8044-1_12 DO - 10.1007/978-1-4419-8044-1_12 ID - Drake2011 ER - TY - JOUR AU - Infante, J. R. AU - Braiteh, F. AU - Emens, L. A. AU - Balmanoukian, A. S. AU - Oaknin, A. AU - Wang, Y. PY - 2016 DA - 2016// TI - Safety, clinical activity and biomarkers of atezolizumab in advanced ovarian cancer JO - Ann Oncol VL - 27 ID - Infante2016 ER - TY - JOUR AU - Lee, J. -. M. AU - Cimino-Mathews, A. AU - Peer, C. J. AU - Zimmer, A. AU - Lipkowitz, S. AU - Annunziata, C. M. PY - 2016 DA - 2016// TI - Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with Poly(ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1–3 inhibitor cediranib in women’s cancer: a dose escalation, phase I study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.34.15_suppl.3015 DO - 10.1200/JCO.2016.34.15_suppl.3015 ID - Lee2016 ER -